fda approved iv glutathione Injection ​FDA: No IV glutathione product

A reasonable clinical estimate: the pharmacokinetic risk of BPC-157 altering apixaban plasma levels is low but not zero

Infrared spectroscopy for structure analysis of protein inclusion bodies, in Inclusion Bodies: Methods and Protocols (Springer), 209223

When methylation is impaired, it can contribute to major chronic conditions, including cardiovascular diseases, infertility, unexplained miscarriages, problems during pregnancy, mood disorders, free radical damage (premature ageing), diabetes, neural tube defects, neurological conditions, chronic fatigue syndrome

Shaking introduces strong shearing forces that can physically break the fragile peptide bonds